Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.0K
6.0K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.4K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.4K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.2K
3.2K
Cancer02:18

Cancer

55.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tobacco and asthma: presenting the world health organization (WHO) tobacco knowledge summary.

Substance abuse treatment, prevention, and policy·2025
Same author

Integrating tobacco cessation in chronic respiratory disease care: a comprehensive approach to reducing the global burden.

BMJ global health·2025
Same author

Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary.

Respiratory research·2024
Same author

SABINA + Hong Kong: a territory wide study of prescribing trends and outcomes associated with the use of short-acting β2 agonists in the Chinese population.

BMC pulmonary medicine·2024
Same author

Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.

OncoTargets and therapy·2015
Same author

Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.

Lung cancer (Amsterdam, Netherlands)·2014

Related Experiment Video

Updated: Mar 20, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Oncogenic driver mutations in lung cancer.

Susan Y Luo1, David Cl Lam2

  • 1Department of Medicine, University of Hong Kong, 102 Pokfulam Road, Hong Kong, SAR, China.

Translational Respiratory Medicine
|May 29, 2016
PubMed
Summary

Understanding lung cancer biomarkers like EGFR, KRAS, ALK, and MET mutations is key for personalized treatment. This review highlights their role in guiding targeted therapies and improving patient outcomes in lung cancer.

Keywords:
ALKDriver mutationsEGFRLung cancer

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

501
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

501
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Lung cancer is a complex disease with diverse molecular characteristics.
  • Genomic and transcriptomic profiling are crucial for understanding cancer biology and guiding treatment.
  • Targeted therapies are effective in specific tumor subsets, necessitating better molecular classification.

Purpose of the Study:

  • To review the clinical significance of key oncogenic driver mutations in lung cancer.
  • To discuss the prognostic and predictive value of these biomarkers for targeted therapies.
  • To emphasize the role of biomarker profiles in personalized lung cancer treatment.

Main Methods:

  • Literature review of genomic and transcriptomic profiling studies in lung cancer.
  • Analysis of clinical studies on oncogenic driver mutations (EGFR, KRAS, EML4-ALK, MET).
  • Evaluation of biomarker data for sensitivity and resistance to targeted therapies.

Main Results:

  • EGFR, KRAS, EML4-ALK, and MET alterations are critical drivers in lung cancer.
  • These mutations have demonstrated prognostic and predictive value in clinical settings.
  • Biomarker profiling enables identification of patients who benefit from specific targeted treatments.

Conclusions:

  • Understanding oncogenic driver mutations is fundamental for personalized lung cancer therapy.
  • Biomarker-driven treatment strategies enhance therapeutic efficacy and patient outcomes.
  • Continued research into molecular phenotypes will advance personalized medicine in lung cancer.